**Biden-Harris Administration Proposes Free OTC Contraception Under ACA** In a significant healthcare policy shift, President Biden and Vice President Harris have proposed offering over-the-counter (OTC) contraceptives without cost-sharing under the Affordable Care Act (ACA). This initiative aims to expand reproductive health access and could have substantial implications for healthcare companies and investors focused on contraception […]

To understand how these large snakes can regenerate their intestines without intestinal crypts, scientists sequenced the RNA genes of pythons. By learning more about this process in reptiles, researchers hope to better inform other scientists working to improve the diagnosis and treatment of gastrointestinal diseases in humans, including diabetes, Crohn’s disease, celiac disease, and cancer.

The Oncology Center of Excellence says it is open to considering the use of artificial intelligence-powered “digital twins” as an alternative to human placebos in clinical trials, but OCE is not quite

      

The Procter & Gamble Company’s Beauty business continued to struggle in China in the firm’s fiscal 2025 first quarter, but performance in North America remained solid, mitigating fears of a broad-

      

UnitedHealth Group saw “rapid acceleration in the prescribing of certain high-cost specialty medications” in its Medicare Advantage prescription drug plans in the third quarter. Prescribing increased

      

Three US states are attempting to intervene in a lawsuit that seeks to roll back changes the Food and Drug Administration made to the abortion pill mifepristone’s Risk Evaluation and Mitigation Stra

      

Fifty-seven percent of surveyed medtech industry leaders say their organization has realized benefits across functions by implementing or scaling GenAI use cases or “quick wins,” according to a new re

      

CINCINNATI–(BUSINESS WIRE)–Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Revenue for the three months ended September 30, 2024 increased 8.3% to $533.3 million, compared to $492.5 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2024 increased 8.1% compared to the third quarter of 2023. Backlog as of September 30

An international study has found that genetic variations in human carbohydrate-active enzymes may affect how people with irritable bowel syndrome (IBS) respond to a carbohydrate-reduced diet.

Telix unveils radiopharmaceutical spinoff Rhine Pharma following string of nuclear medicine acquisitions
fkansteiner
Tue, 10/22/2024 – 14:31